1. media clips

Emerging developments in dry eye

August 1, 2017 - Rod McNeil on Eye News
An estimated 344 million people worldwide suffer from dry eye [1]. This chronic syndrome is characterised by a vicious cycle of tear film hyperosmolarity, tear instability and corneal stress, leading to increased friction, inflammation, ocular surface damage and decreased visual acuity. The author reviews emerging developments focused on improving treatment success.

The Tear Film & Ocular Surface Society (TFOS) Dry Eye Workshop II (DEWS II) global consensus report represents the first evidence-based reexamination of multiple aspects of dry eye disease (DED) since the initial international seminal DEWS report issued in 2007. TFOS DEWS II sought over the past two years to update the definition, classification and diagnosis of DED, critically evaluate the epidemiology, pathophysiology, mechanism, and impact of this disorder, address its management and therapy and develop recommendations for the design of clinical trials to assess pharmaceutical interventions for DED treatment.

DEWS II has redefined dry eye as a multifactorial disease of the ocular surface characterised by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play aetiological roles.

continue reading article

20 April

TFOS Guidelines

Ocular surface disease (OSD)—including dry eye disease, blepharitis, meibomian gland dysfunction, conjunctival inflammation, and cicatrizing ocular surface disorders—is one of the most common and underrecognized factors affecting the success of eye surgery (e.g., refractive, cataract, glaucoma, strabismus, retina, and oculoplastic). Conversely, optimizing the ocular surface is one of the most effective, modifiable strategies for enhancing surgical success across all ophthalmic subspecialties. And the central clinical principle appears to be universal: elective eye surgery...

17 April

EssilorLuxottica Partners with TFOS to Advance Ocular Surface Health Worldwide

TFOS is pleased to announce a new strategic partnership with EssilorLuxottica, a global leader in vision care and eyewear. This collaboration will support shared efforts to elevate awareness, education, and scientific progress in tear film and ocular surface health worldwide. By combining TFOS’s expertise in evidence-based consensus and professional education with EssilorLuxottica’s global reach and innovation capabilities, the partnership aims to help improve standards of care for patients affected by dry eye disease and related ocular surface conditions. Together, TFOS and EssilorLuxottica...

10 February

Latin American TFOS Ambassador Meeting

TFOS has organized a special meeting of the Latin American TFOS Ambassadors. This meeting, which will occur in Panama City this May, has two goals: first, to address the unmet needs for the management (e.g. diagnosis & treatment) of ocular surface diseases in their country/region, as well as what the Ambassadors perceive as short and long term scientific/clinical solutions; and second, to create a report for publication in a peer-reviewed journal. Participants will include TFOS Ambassadors from Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras,...

Corporate Advisory Board Members